Structure Therapeutics, Inc.: Promising Advances in Metabolic Treatments Drive Buy Recommendation
BMO Capital analyst Evan Seigerman has reiterated their bullish stance on GPCR stock, giving a Buy rating on November 5. Evan Seigerman has ...
Schrodinger’s Promising Growth Potential Highlighted by Novartis Partnership and Strong Fundamentals
In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Schrodinger (SDGR – Research Report), with a ...
Merck signs up to $3.3 billion cancer drug deal with China-based LaNova
Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...
BioSpace8d
Gilead Beats Q3 Expectations Fueled by HIV Drug Sales, Raises Full-Year Guidance
BMO Capital Markets analyst Evan Seigerman in a note to investors called Gilead’s third-quarter performance “consistent” and ...
BioSpace15d
Amgen Whets Investors’ Appetites for MariTide Obesity Data by End of Year
While Amgen’s third-quarter financial results on Wednesday were “somewhat uneventful,” investors continue to be focused on ...
Amgen posts higher profit, obesity data on track for late this year
Amgen reported a higher quarterly profit on Wednesday, driven by a 24% rise in sales of drugs for high cholesterol and ...
Viking slips as manufacturing concerns cloud promising oral obesity drug data
Viking Therapeutics shares reversed course to fall 11% on Monday as focus shifted to the drug developer's ability to mass ...
Yahoo Finance17d
Amgen posts higher profit, obesity data on track for late this year
The financial results were somewhat uneventful, BMO Capital Markets analyst Evan Seigerman said in a research note, as investor focus shifts to the upcoming readout of Phase 2 results for the ...
Regeneron shares drop as higher-dose Eylea drug misses sales estimates
"Investors are likely to question a second sequential miss for Eylea HD, given its importance to the growth story," said BMO ...
Eylea headwinds said to be behind Regeneron’s post-Q3 plunge
Regeneron Pharmaceuticals (REGN) stock falls despite Q3 beat, a move attributed to lower-than-expected sales for its high-dose Eylea therapy. Read more here.